Review of the safety and efficacy of risedronate for the treatment of male osteoporosis

Figures & data

Table 1 Summary of randomized controlled trials of risedronate for the treatment of male osteoporosis

Condition	Design	n	RIS dose (mg)	BMD LS (%)	BMD FN (%)	Vert fracture	Hip fracture
Primary OP (Boonen 2006) 24 months	RCT	191	35 per wk	4.5	NR	NR	NR
		93	Pla	NR	NR	NR	NR
Primary and Secondary OP (Ringe 2003) 12 months	RCT	158	5 per day	4.7	1.8	5.1%	NR
		158	Pla	1.0	0.2	12.7%	NR
CIOP prevention (Reid 2000, 2001) 12 months	RCT	184	2.5 or 5 perday	0.8a	1.5a	Ris 9% Pla 24%	NR
			Pla	−3.4	−3.3	Pooled	NR
CIOP treatment (Reid 2001; Cohen 1999) 12 months			2.5 or 5 perday	4.8a	2.1a	2.5/5 mg vs placebo 82.4% reduction (p = 0.008)	NR
			Pla	1.2	−0.2		NR
Post-stroke (Sato 2005) 18 months	RCT	140	2.5/day	2.5b	NR	NR	1.4
		140	Pla	−3.5b	NR	NR	7.1
Hyperthyroidism (Majima 2006) 12 months	RCT	14	2.5	6.07	4.41	NR	NR
		13	Pla	1.90	2.61	NR	NR
IBD (Henderson 2006) 12 months	RCT	total 61	5	2.9	3.1	NR	NR
		male 25	Pla	1.04	0.1	NR	NR
Transplantation (Tauchmanova 2003) 12 months	RCT	total 34	5	5.9	1.3	NR	NR
		male 16	Pla	1.1	−4.2	NR	NR
Leprosy (Kanaji 2006) 9 months	RCT	12	2.5	4.8c	NR	0.82**	NR
		11	Pla	0.9c	NR	1.88	NR
Stress fractures (Milgrom 2004) 3 months	RCT	165	30 for 2 weeks then 30 weekly	N/A	N/A	N/A	14.5
		159	Pla	N/A	N/A	N/A	13.2

^a BMD change with 5 mg dose

^b metacarpal BMD

^c estimate from graph

** p < 0.05

Abbreviations: BMD, bone mineral density; CIOP, corticosteroid-induced osteoporosis; IBD, inflammatory bowel disease; NR, not reported; OP, osteoporosis; Pla, placebo; RIS, risedronate; RCT, randomized controlled trial.

Figure 1 Risedronate in the treatment of corticosteroid-induced osteoporosis.

Figure 2 Risedronate in the prevention of corticosteroid-induced osteoporosis.

Figure 3 Vertebral fracture incidence.

BoonenSDelmasPDWenderothDH2006Risedronate shown to be safe and effective in men with osteoporosis in a 2-year, double-blind, randomized, placebo-controlled, multicentre studyOsteoporos Int17S23031

 Web of Science ®Google Scholar

RingeJD2003[Osteoporosis in men]Dtsch Med Wochenschr1289252812715292

 PubMed Web of Science ®Google Scholar

ReidDMHughesRALaanRF2000Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment studyJ Bone Miner Res1510061310841169

 PubMed Web of Science ®Google Scholar

ReidDMAdamiSDevogelaerJP2001Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapyCalcif Tissue Int692424711730260

 PubMed Web of Science ®Google Scholar

CohenSLevyRMKellerM1999Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis Rheum4223091810555025

 PubMed Web of Science ®Google Scholar

SatoYIwamotoJKanokoT2005Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after strokeArch Intern Med16517434816087822

 PubMed Web of Science ®Google Scholar

MajimaTKomatsuYDoiK2006Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves’ diseaseJ Bone Miner Metab241051316502116

 PubMed Web of Science ®Google Scholar

HendersonSHoffmanNPrinceR2006A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel diseaseAm J Gastroenterol1011192316405543

 PubMed Web of Science ®Google Scholar

TauchmanovaLSelleriCEspositoM2003Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignanciesOsteoporos Int1410131914517597

 PubMed Web of Science ®Google Scholar

KanajiAHigashiMNamisatoM2006Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosyLepr Rev771475316895071

 PubMed Web of Science ®Google Scholar

MilgromCFinestoneANovackV2004The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruitsBone354182415268892

 PubMed Web of Science ®Google Scholar